As a new generation highly selective JAK3/TEC dual inhibitor, Ritlecitinib launched by Lao Big Bear Pharmaceutical brings new hope for treatment to global patients with its potential for precise intervention in autoimmune diseases such as alopecia areata.
Is there a generic version of Ritlecitinib in Laos?
Yes, there is a generic version of Ritlecitinib in Laos. Lao Big Bear Pharmaceutical's generic Ritlecitinib is available in the specification of 50mg*28 capsules/box. For more information, it is recommended that you consult a professional customer service.
Indications of Ritlecitinib
In the field of alopecia areata treatment, the approval of Ritlecitinib marks the successful launch of the second JAK inhibitor following Olumiant, bringing new hope to patients suffering from this condition. Notably, Ritlecitinib is the first new drug approved for the treatment of alopecia areata in adolescents aged 12 years and older, filling the gap in targeted treatment for this age group. This drug is developed and manufactured by the globally renowned Pfizer, provided in capsule form, with each capsule containing 50mg of ritlecitinib. Its brand name is Ritlecitinib, and it should be stored at room temperature between 20°C and 25°C, protected from light, with brief excursions permitted between 15°C and 30°C. As a kinase inhibitor, Ritlecitinib exerts its therapeutic effect by precisely blocking specific signaling pathways. Its approval not only enriches the treatment options for alopecia areata but also reflects the medical community's special attention to adolescent patients, as alopecia areata often has a more profound impact on the psychological development and quality of life of teenagers. With once-daily oral administration, the drug aims to help patients regrow hair and restore confidence. However, healthcare professionals must strictly adhere to its usage restrictions when prescribing, namely not recommending its use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants, to ensure the safety and efficacy of the treatment.
Detailed explanation of the indications, recommended dosage, and administration of Ritlecitinib
Ritlecitinib is indicated for the treatment of severe alopecia areata in adults and adolescents aged 12 years and older. Prior to using this drug, physicians must conduct a series of thorough assessments and immunizations. First, an evaluation for tuberculosis (TB) infection is mandatory; patients with active TB should not use this drug. For patients with latent TB or those at high risk, preventive treatment should be initiated before starting the drug. Second, screening for viral hepatitis should be performed according to clinical guidelines; patients with hepatitis B or C are not recommended to use this drug. Additionally, use of Ritlecitinib is absolutely contraindicated when the absolute lymphocyte count (ALC) is below 500/mm³ or the platelet count is below 100,000/mm³. Finally, relevant vaccinations should be updated for patients according to the latest immunization guidelines. After completing the above assessments, the recommended dosage is 50 mg once daily. Patients may take it with or without food, but the capsule must be swallowed whole, without crushing, opening, or chewing. If a dose is missed, it should be taken as soon as possible, but if it is less than 8 hours until the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Regarding overdose, clinical trials have shown no specific toxicity when a single oral dose up to 800 mg is administered, and more than 90% of the drug is expected to be eliminated within 48 hours, but there is no specific antidote; treatment should be based on symptomatic supportive care. It is important to note that Ritlecitinib is not recommended for use in patients with severe hepatic impairment (Child-Pugh class C).
